The other CCR5 antagonist (DAPTA) was shown to be effective in the case of partial sciatic-nerve-ligation-induced hypersensitivity [53], but it was ineffective in STZ-induced [13] and CCI-induced (own unpublished data) neuropathy. This evidence concerns the gene CCR5 and neuropathy.